Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production
Background Magnesium is an antagonist of the N-methyl-D-aspartate receptor. This study aimed to investigate the anti-edematous effect of magnesium sulfate (MS) in different protocols of use and the possible mechanism of its action. Methods In a rat model of carrageenan-induced paw inflammation, the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-02-01
|
| Series: | Dose-Response |
| Online Access: | https://doi.org/10.1177/15593258231155788 |
| _version_ | 1811173141207056384 |
|---|---|
| author | Dragana Srebro Branko Dožić Katarina Savić Vujović Branislava Medić Brkić Sonja Vučković |
| author_facet | Dragana Srebro Branko Dožić Katarina Savić Vujović Branislava Medić Brkić Sonja Vučković |
| author_sort | Dragana Srebro |
| collection | DOAJ |
| description | Background Magnesium is an antagonist of the N-methyl-D-aspartate receptor. This study aimed to investigate the anti-edematous effect of magnesium sulfate (MS) in different protocols of use and the possible mechanism of its action. Methods In a rat model of carrageenan-induced paw inflammation, the anti-edematous activity of MS was assessed with a plethysmometer. The effects of the nonselective inhibitor (L-NAME), selective inhibitor of neuronal (L-NPA) and inducible (SMT) nitric oxide synthase on the effects of MS were evaluated. Results MS administered systemically before or after inflammation reduced edema by 30% (5 mg/kg, P < .05) and 55% (30 mg/kg, P < .05). MS administered locally (.5 mg/paw, P < .05) significantly prevented the development of inflammatory edema by 60%. L-NAME, intraperitoneally administered before MS, potentiated (5 mg/kg, P < .05) or reduced (3 mg/kg, P < .05), while in the highest tested dose L-NPA (2 mg/kg, P < .01) and SMT (.015 mg/kg, P < .01) reduced the anti-edematous effect of MS. Conclusions Magnesium is a more effective anti-edematous drug in therapy than for preventing inflammatory edema. The effect of MS is achieved after systemic and local peripheral administration and when MS is administered as a single drug in a single dose. This effect is mediated at least in part via the production of nitric oxide. |
| first_indexed | 2024-04-10T17:42:55Z |
| format | Article |
| id | doaj.art-26ca3828ae1c4c7590f9521ad63126f2 |
| institution | Directory Open Access Journal |
| issn | 1559-3258 |
| language | English |
| last_indexed | 2024-04-10T17:42:55Z |
| publishDate | 2023-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Dose-Response |
| spelling | doaj.art-26ca3828ae1c4c7590f9521ad63126f22023-02-03T08:03:24ZengSAGE PublishingDose-Response1559-32582023-02-012110.1177/15593258231155788Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide ProductionDragana SrebroBranko DožićKatarina Savić VujovićBranislava Medić BrkićSonja VučkovićBackground Magnesium is an antagonist of the N-methyl-D-aspartate receptor. This study aimed to investigate the anti-edematous effect of magnesium sulfate (MS) in different protocols of use and the possible mechanism of its action. Methods In a rat model of carrageenan-induced paw inflammation, the anti-edematous activity of MS was assessed with a plethysmometer. The effects of the nonselective inhibitor (L-NAME), selective inhibitor of neuronal (L-NPA) and inducible (SMT) nitric oxide synthase on the effects of MS were evaluated. Results MS administered systemically before or after inflammation reduced edema by 30% (5 mg/kg, P < .05) and 55% (30 mg/kg, P < .05). MS administered locally (.5 mg/paw, P < .05) significantly prevented the development of inflammatory edema by 60%. L-NAME, intraperitoneally administered before MS, potentiated (5 mg/kg, P < .05) or reduced (3 mg/kg, P < .05), while in the highest tested dose L-NPA (2 mg/kg, P < .01) and SMT (.015 mg/kg, P < .01) reduced the anti-edematous effect of MS. Conclusions Magnesium is a more effective anti-edematous drug in therapy than for preventing inflammatory edema. The effect of MS is achieved after systemic and local peripheral administration and when MS is administered as a single drug in a single dose. This effect is mediated at least in part via the production of nitric oxide.https://doi.org/10.1177/15593258231155788 |
| spellingShingle | Dragana Srebro Branko Dožić Katarina Savić Vujović Branislava Medić Brkić Sonja Vučković Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production Dose-Response |
| title | Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production |
| title_full | Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production |
| title_fullStr | Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production |
| title_full_unstemmed | Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production |
| title_short | Magnesium Sulfate Reduces Carrageenan-Induced Rat Paw Inflammatory Edema Via Nitric Oxide Production |
| title_sort | magnesium sulfate reduces carrageenan induced rat paw inflammatory edema via nitric oxide production |
| url | https://doi.org/10.1177/15593258231155788 |
| work_keys_str_mv | AT draganasrebro magnesiumsulfatereducescarrageenaninducedratpawinflammatoryedemavianitricoxideproduction AT brankodozic magnesiumsulfatereducescarrageenaninducedratpawinflammatoryedemavianitricoxideproduction AT katarinasavicvujovic magnesiumsulfatereducescarrageenaninducedratpawinflammatoryedemavianitricoxideproduction AT branislavamedicbrkic magnesiumsulfatereducescarrageenaninducedratpawinflammatoryedemavianitricoxideproduction AT sonjavuckovic magnesiumsulfatereducescarrageenaninducedratpawinflammatoryedemavianitricoxideproduction |